National and Kapodistrian University of Athens
Πρόγνωση και παθογένεια των αυτοάνοσων συστηματικών εκδηλώσεων στους ασθενείς με μυελοδυσπλαστικό σύνδρομο: ο ρόλος του μεταγραφικού παράγοντα IRF-1 (interferon regulatory factor-1)
Abstract
dc:descriptionPrimary myelodysplastic syndromes (MDS) are clonal disorders of the hematopoietic stem cell characterized by ineffective and dysplastic hematopoiesis and peripheral cytopenias. A distinct subset of MDS patients manifests overt autoimmune manifestations (AIMs), the underlying pathogenesis and prognostic significance of which still remain controversial. The estimated incidence of AIMs in MDS has increased by 12-20% in previous studies. Clinical manifestations of such phenomena may include systemic vasculitic syndrome, skin vasculitis, arthritis, autoimmune cytopenias, peripheral polyneuropathy, and inflammatory bowel disease, even classical connective tissue disorders such as relapsing polychondritis.In order to identify potential pathophysiological mechanisms involved in this phenomenon we investigated whether Interferon Regulatory Factor-1 (IRF-1) is implicated in the pathophysiology of AIMs in MDS. IRF-1 originally identified as an IFNß promoter binding factor, as well as a mediator for IFN signaling, was subsequently recognized as a transcription factor involved in cell growth control, induction of apoptosis and susceptibility to transformation by oncogenes, playing an essential role in surveillance against malignant development. Deletions and somatic mutations of IRF-1 gene have been implicated in the multiphase process towards human myelodysplasia and leukemic evolution. Furthermore, alternative splicing of the IRF-1 mRNA resulting in truncated non-functional transcripts has been observed at high frequencies in patients with MDS. Thus accelerated exon skipping of IRF-1 has been considered as a possible mechanism of functional inactivation of IRF-1 in myelodysplasia. Beyond its tumor suppressor function, IRF-1 regulates multiple stages of the immune response such as induction of IL-12 and Thl differentiation as well as MHC II, CD8 T and NK cells maturation. IRF-1 is involved in the induction of inflammatory response regulating the expression of inflammation-related enzymes,10like inducible nitric oxide synthase and cyclooxygenase-2 and amplifying the TNF- induced vascular cell adhesion molecule 1 (VCAM-1) expression. This evidence reveals that IRF-1 is a transcriptional activator linking immune response and oncogenesis.We investigated IRF-1 mRNA expression in bone marrow mononuclear cells (BMMCs) of 7 MDS patients with AIMs and 7 MDS patients without AIMs, while 5 patients with systemic vasculitis were used as controls. The selection of patients with systemic vasculitis as controls was based on the fact that_vasculitic syndromes were the commonest AIMs in our MDS patients. Bone marrow aspirates, biopsies and cytogenetic data from all patients and controls were obtained. MDS patients were classified according to the FAB classification and were also categorized according to the IPSS prognostic system. The expression of IRF-1 full length mRNA (IRF-1-FL) was studied by a Relative Quantitative RT-PCR (reverse transcription polymerase chain reaction). IRF-1 transcripts were compared between multiple samples, using 18S rRNA as a co-amplified internal control for sample normalization. Results are expressed as the ratio between the optical density of IRF-1 amplicon and optical density of the 18S amplicon, a method yielding a corrected relative value for the IRF- 1 product in each sample. A nested PCR assay was used in order to amplify the entire IRF-1 mRNA. The resulting PCR products were separated on a 2% agarose gel and were then photographed, whilst the band mean intensity (BMI) of IRF-1-FL and 18S were analyzed by the appropriate software.We found that MDS patients with AIMs displayed elevated, intact, IRF-1-FL mRNA levels in their BMMCs compared with MDS patients without AIMs. Further more, patients with AIMs expressed IRF-1 -FL at a level almost equal to that of patients with systemic vasculitis. Low expression of IRF-1 was established in all seven patients without AIMs and this was in conjuction with exon skipping events, further supporting the possible role of IRF-1 gene inactivation in relation to the pathology of MDS.Recent findings implicate IRF-1 in VCAM-1 expression and nitric oxide synthase production, adding a possible pathophysiological link between increased IRF-1 expression and vasculitis. In this regard, the absence of IRF-1 expression in MDS patients without AIMs, appear to protect them against the development of the vasculitic syndrome. Our results are in agreement with in vivo models of IRF-1 - deficient mice manifesting a reduced incidence and severity of type II collagen-11induced arthritis and experimental allergic encephalomyelitis compared with the wild type mice.Previous retrospective studies have established a link between MDS and AIMs and illustrated clinical aspects of these association. In these studies, it is highlighted that MDS/AIMs patients display poor prognosis. However the prognostic significance of the coexisting autoimmune disorder in MDS could prove problematic owing to the fact that underlying hematological disease is also remarkably heterogeneous in regard to the prognosis.We studied 70 MDS patients diagnosed at the Department of Pathophysiology, Medical School of Athens, over a period of 4 years. In prospective, our study tried to determine the clinical aspects and evolution of AIMs in patients with MDS and to ascertain the prognostic implications of these manifestations in MDS. Thirteen MDS patients developed AIMS with ages ranging from 51 to 80 years. All relevant information, including FAB category and IPSS prognostic subcategory, haematological profile, cytogenetic analysis, treatment, evolution of the haemopathy, transformation to acute leukemia and overall survival was provided. The IPSS prognostic index is a product of pooled data from previous scoring systems predicting survival and evolution to AML in MDS patients, and should therefore considered when assessing the clinical significance and prognosis of any other coexisted clinical parameter, such as AIMs, in MDS.The patients with AIMs were not statistically different in survival from patients without AIMs, a finding that contrasts with previously published data. No correlation between FAB subcategory and IPSS grade with predisposition to development of AIMs was observed. It would be emphasized that while the survival and prognosis of the MDS patients was not influenced by the presence of AIMs, IPSS was an important prognostic parameter in the MDS patients with AIMs. The fact that all deaths in the group of MDS patients were_owing to myelodysplasia-related complications and occurred in the high-risk IPSS category further confirms our findings.We conclude that the prognosis and mortality of MDS patients manifesting AIMs is closely related to the primary haematological disorder.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2004
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Giannouli, Stavroula
- Γιαννούλη, Σταυρούλα
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/24807